NYSE:HIMSHealthcare
Will Novo Nordisk’s GLP-1 Telehealth Tie-Up Change Hims & Hers Health's (HIMS) Cash-Pay Narrative
Earlier this year, Novo Nordisk announced a partnership with Hims & Hers Health to offer branded GLP-1 weight-loss drugs through the Hims & Hers telehealth platform, with subscriptions priced at US$39 for the first month and US$149 thereafter, excluding medication costs.
The tie-up positions Hims & Hers as a key telehealth partner for Novo Nordisk at a time when some employers are limiting GLP-1 coverage, potentially directing more cash-pay patients toward its platform.
Next, we’ll examine...